


 Cite this: *RSC Adv.*, 2022, **12**, 3136

## Antimicrobial activity of silver sulfide quantum dots functionalized with highly conjugated Schiff bases in a one-step synthesis†

 Nurulizzatul Ningsheh M. Shahri,<sup>a</sup> Hussein Taha,<sup>b</sup> Malai Haniti S. A. Hamid,<sup>a</sup> Eny Kusrini,<sup>c</sup> Jun-Wei Lim,<sup>d</sup> Jonathan Hobley<sup>e</sup> and Anwar Usman<sup>a</sup>

In the present paper, low-dimensional  $\text{Ag}_2\text{S}$  QDs were fabricated for the first time, with four different dithiocarbazate derivative Schiff bases (SB) as capping agents in a one-pot synthesis. These SB-capped  $\text{Ag}_2\text{S}$  QDs were almost spherical with an average size range of 4.0 to 5.6 nm, which is slightly smaller than conventional thioglycolic acid (TGA)-capped  $\text{Ag}_2\text{S}$  QDs. We demonstrate that the growth of Gram-positive bacteria (*Bacillus subtilis* and *Staphylococcus aureus*), Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*), and a prevalent fungal pathogen (*Candida albicans*) are inhibited more when the bacterial and fungal cells were nurtured with the synthesized SB- $\text{Ag}_2\text{S}$  QDs, compared with TGA- $\text{Ag}_2\text{S}$  QDs or free unbound Schiff bases. The minimum inhibitory concentration (MIC) results confirmed that even low concentrations of SB- $\text{Ag}_2\text{S}$  QDs were able to inhibit bacterial (MIC 5–75  $\mu\text{g mL}^{-1}$ ) and fungal growth (MIC 80–310  $\mu\text{g mL}^{-1}$ ), and in some cases they performed better than streptomycin (8–25  $\mu\text{g mL}^{-1}$ ). Lethality bioassay results confirmed that SB- $\text{Ag}_2\text{S}$  QDs were not toxic to brine shrimp (*Artemia salina*). The results show that capping agents are essential in the design of functional  $\text{Ag}_2\text{S}$  QDs, and highlight that Schiff bases provide an excellent opportunity to optimize the biological activities of silver based QDs.

 Received 11th November 2021  
 Accepted 14th January 2022

 DOI: 10.1039/d1ra08296e  
[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

### 1. Introduction

In general, photo-excited quantum dots (QDs) emit bright, sharp and tunable light emission from the UV to the near infrared (NIR) making them suitable for bioimaging. In particular, they can be used to substitute toxic synthetic dyes in diagnostics, cancer therapies,<sup>1</sup> and as antibacterial agents.<sup>2</sup> Among them, silver sulfide ( $\text{Ag}_2\text{S}$ ) QDs have received much attention for biomedical applications, due to their high chemical stability,<sup>3</sup> good photo-stability,<sup>4</sup> broad optical absorption spectrum,<sup>5,6</sup> and non-toxic properties.<sup>7</sup> With their narrow bandgap energy ( $\sim 1$  eV),<sup>8</sup>  $\text{Ag}_2\text{S}$  QDs are the most important nanometer-sized materials to be developed for biocompatible

NIR-QDs for *in vivo* optical imaging.<sup>9–13</sup> In addition, under intense light excitation they produce a large photothermal effect and have good heat dissipation properties which makes them potential candidates for *in situ* photothermal cancer therapeutics.<sup>2,14</sup> The great promise of  $\text{Ag}_2\text{S}$  QDs in biomedical applications demands further explorative and challenging research, in order to realize their full potential.

It has been demonstrated that capping agents play an important role in developing photostable QDs.<sup>15</sup> However, capping agents can also be used to harness and control chemical reactions on their surface.<sup>16</sup> For example,  $\text{CdS}$  QDs capped with thiols, nitroxides, and surfactants can be used to detect peptides, tyrosine, cysteine, and organic radicals.<sup>17,18</sup> In addition, QDs capped with biodegradable, biocompatible, and compounds with low toxicity from bacteria<sup>19</sup> or plant leaves<sup>20</sup> have been used to suppress the growth of A549 lung cancer cell.<sup>20</sup> In this vein, Schiff bases also offer an opportunity to be used as a strategic design of capping agents as they also exhibit antimicrobial,<sup>21,22</sup> antifungal,<sup>23,24</sup> anti-inflammatory,<sup>25</sup> and anti-cancer activities.<sup>26</sup> Furthermore, conjugated Schiff bases, with a corresponding reduction in their LUMO level may promote electron transfer from the  $\text{Ag}_2\text{S}$  core which may enhance the anti-pathogen activities of the QD. This is because the Fermi level of  $\text{Ag}_2\text{S}$  is high in energy (absolute level  $\sim 10$  eV as determined by photoelectron spectroscopy) and the bandgap is low enough in energy that the conduction band is easily populated

<sup>a</sup>Chemical Sciences, Faculty of Science, Universiti Brunei Darussalam, Jalan Tunku Link, Gadong BE1410, Brunei Darussalam. E-mail: anwar.usman@ubd.edu.bn

<sup>b</sup>Environmental and Life Sciences, Faculty of Science, Universiti Brunei Darussalam, Jalan Tunku Link, Gadong, BE1410, Brunei Darussalam

<sup>c</sup>Department of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus Baru UI-Depok, 16424, Indonesia

<sup>d</sup>Department of Fundamental and Applied Sciences, HICoE-Centre for Biofuel and Biochemical Research, Institute of Self-Sustainable Building, Universiti Teknologi PETRONAS, 32610 Seri Iskandar, Perak Darul Ridzuan, Malaysia

<sup>e</sup>Department of Biomedical Engineering, National Cheng Kung University, 1, University Road, Tainan City 701, Taiwan, ROC

† Electronic supplementary information (ESI) available. See DOI: [10.1039/d1ra08296e](https://doi.org/10.1039/d1ra08296e)



at room temperature.<sup>8,27,28</sup> For this reason  $\text{Ag}_2\text{S}$  has often been used as an electron injector or shuttle in hybrid catalytic and light harvesting systems.<sup>27,28</sup>

Size-controlled  $\text{Ag}_2\text{S}$  QDs have been synthesized by various methods, including the single precursor,<sup>3</sup> one-pot synthesis,<sup>29</sup> hydrothermal,<sup>30</sup> water-phase microwave,<sup>31</sup> liquid–liquid interface reaction,<sup>32</sup> and reverse microemulsion methods.<sup>33,34</sup> The capping agents used to passivate the atoms on the QD surface, which are important to stabilize and prevent the nanocrystalline structures from aggregating, include surfactant (cetyltrimethyl ammonium bromide),<sup>35</sup> sodium dodecyl sulfate,<sup>36</sup> Schiff-base (2-(benzylidene amino)azobenzothiol) ligand,<sup>37</sup> ethylenediaminetetraacetic acid (EDTA),<sup>38</sup> 2-mercaptopropioic acid (2-MPA),<sup>10,39</sup> thioglycolic acid (TGA),<sup>40</sup> and/or a carbon-containing shells.<sup>41</sup>

The objective of this study was to develop NIR active  $\text{Ag}_2\text{S}$  QDs in a one-pot synthesis with four different Schiff bases (SB) as stabilizing agents. These SB- $\text{Ag}_2\text{S}$  QDs are reported for the first time. The SB- $\text{Ag}_2\text{S}$  QDs were screened for antibacterial activity against Gram-positive and Gram-negative, namely *Bacillus subtilis*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Staphylococcus aureus* bacterial strains, as well as for their antifungal activities against *Candida albicans*. The detailed antimicrobial activities of the SB- $\text{Ag}_2\text{S}$  QDs were further evaluated by determining their minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The cytotoxicity of the SB- $\text{Ag}_2\text{S}$  QDs was assessed using the brine shrimp lethality bioassay. The results were systematically evaluated and compared with the antimicrobial activities of the conventional TGA-capped  $\text{Ag}_2\text{S}$  QDs and the respective free Schiff bases. It was found that the  $\text{Ag}_2\text{S}$  nanocrystal structure and Schiff bases capping agents played a synergistic effect in the antibacterial activity, as reflected by the better biological activity of the SB- $\text{Ag}_2\text{S}$  QDs. Based on our results and established literature we propose that the mechanism of antimicrobial activity of Schiff base-capped  $\text{Ag}_2\text{S}$  QDs can be explained by a thermally initiated electron transfer model,<sup>8,27,28,42</sup> providing new insight into the mode of action of their anti-pathogenic activity.

## 2. Experimental

### 2.1 Materials and reagents

Silver nitrate ( $\text{AgNO}_3$ ), sodium sulfide ( $\text{Na}_2\text{S} \cdot 9\text{H}_2\text{O}$ ), and thioglycolic acid ( $\text{C}_2\text{H}_4\text{O}_2\text{S}$ ) were purchased from Sigma Aldrich. Acetylpyrazine ( $\text{C}_6\text{H}_6\text{N}_2\text{O}$ ), 9-anthracenecarboxaldehyde ( $\text{C}_{15}\text{H}_{10}\text{O}$ ), hydrazine hydrate ( $\text{H}_6\text{N}_2\text{O}$ ), potassium hydroxide (KOH), carbon disulfide ( $\text{CS}_2$ ), and other reagents of analytical grade were respectively obtained from Merck, Fluka, Alpha Chemika, and R & M Chemicals. All chemical and reagents were used as received.

### 2.2 Synthesis of Schiff bases

The chemical structures of Schiff bases of *S*-methyl- and *S*-benzyl-dithiocarbazate derivatives used in this study are shown in Fig. 1. The Schiff bases were synthesized based on the




Fig. 1 The chemical structures of Schiff bases used as capping agents in this study.

procedures reported by Hamid *et al.*<sup>43</sup> In general, hydrazine hydrate was added to a solution of KOH in ethanol, and the solution was cooled in an ice-salt bath.  $\text{CS}_2$  was then added dropwise with constant stirring, resulting in the formation of two layers. The aqueous layer was then separated using a separating funnel, and poured into cold ethanol. Either methyl iodide or benzyl chloride was then added to the solution with vigorous stirring, giving white precipitate of the *S*-methyl- or *S*-benzyl-dithiocarbazates, respectively, which were then isolated and purified by recrystallization from absolute ethanol. The purified *S*-methyl- or *S*-benzyl-dithiocarbazates were then dissolved in hot ethanol and mixed with equimolar amounts of either 9-anthracenecarboxaldehyde or acetylpyrazine solutions to give four different Schiff bases; *i.e.* methyl (2Z)-2-[(anthracen-9-yl)methylidene]hydrazine-1-carbo-dithioate (**9anSM**), benzyl (2E)-2-[(anthracen-9-yl)methylidene]hydrazine-1-carbodithioate (**9anSB**), methyl (2E)-2-[1-(pyrazin-2-yl)ethylidene]hydrazine-1-carbodithioate (**AcpySM**), benzyl (2E)-2-[1-(pyrazin-2-yl)ethylidene]hydrazine-1-carbodithioate (**AcpySB**). The detailed syntheses and chemical characterization of the Schiff bases are described in ESI.†

### 2.3 Preparation of $\text{Ag}_2\text{S}$ QDs

The SB- $\text{Ag}_2\text{S}$  QDs were synthesized as reported by Vardar *et al.*<sup>39</sup> and Zhang *et al.*<sup>44</sup> with some modifications.  $4.2 \times 10^{-3}$  moles of  $\text{AgNO}_3$  (0.7135 g) were dissolved 120 mL of ultrapure water in a three-necked flask under an atmosphere of nitrogen for 20 min. The pH was adjusted to 7.5 by adding NaOH and  $\text{CH}_3\text{COOH}$  to form a clear solution.  $1 \times 10^{-3}$  moles of each Schiff base was dissolved in 10 mL of dimethylformamide and was added to the  $\text{AgNO}_3$  solution whilst stirring. The solution was then ready for the next phase. TGA- $\text{Ag}_2\text{S}$  QDs were synthesized with a similar procedure.  $5.7 \times 10^{-3}$  moles of TGA (0.40 mL) were added to the  $\text{AgNO}_3$  solution whilst stirring. The pH of all the mixtures was then readjusted to 7.5 to form a yellow solution. The solution was then ready for the next phase.



The next phase was the same for both SB- $\text{Ag}_2\text{S}$  QDs and TGA- $\text{Ag}_2\text{S}$  QDs.  $2.1 \times 10^{-3}$  moles of  $\text{Na}_2\text{S}$  (0.1635 g) were added to each QD solution, respectively under nitrogen bubbling, to prevent the oxidation of  $\text{S}^{2-}$ , while stirring for 20 min until a dark brown solution formed. The mixtures were then refluxed at 100 °C for 5 minutes. After cooling, the SB- $\text{Ag}_2\text{S}$  QDs and TGA- $\text{Ag}_2\text{S}$  QDs were isolated as a dark grey solid precipitate, and they were purified by repetitive centrifugation and washing in acetone and ultrapure water. These  $\text{Ag}_2\text{S}$  QDs were kept as an aqueous colloidal solution until use.

#### 2.4 Measurements and characterization of $\text{Ag}_2\text{S}$ QDs

The elemental composition of the SB- $\text{Ag}_2\text{S}$  QDs and TGA- $\text{Ag}_2\text{S}$  QDs were analyzed by scanning electron microscopy (SEM) combined with energy-dispersive X-ray spectroscopy (EDX) using a JSM-7600F SEM (JEOL, Japan) operating at 5.0 kV. Their shape and crystalline properties were evaluated by high resolution transmission electron microscopy (HRTEM) using an HT7830 microscope (Hitachi, Japan). Their size distributions were estimated from the TEM images.

Their electronic absorption spectra in the visible to NIR region (600–1100 nm) were recorded for dilute aqueous colloidal solutions in 1 cm cuvette on a UV-1900 spectrometer (Shimadzu, Japan). Their vibrational spectra in the range of 500–4000  $\text{cm}^{-1}$  were measured in KBr disks on a Fourier transform infrared (FTIR) Prestige21 spectrophotometer (Shimadzu, Japan).

Their crystalline phase was determined by X-ray diffraction (XRD) measured with an angle of  $2\theta$  from 5°–80° on an Empyrean Diffractometer (PANalytical, The Netherlands) with Mo  $\text{K}\alpha$  radiation ( $\lambda = 0.7107 \text{ \AA}$ ) under ambient condition.

#### 2.5 Bacterial growth inhibition

The antibacterial activity of the SB- $\text{Ag}_2\text{S}$  QDs were screened against both Gram-positive (*Bacillus subtilis* ATCC6633 and *Staphylococcus aureus* ATCC 25923) and Gram-negative (*Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853) using the agar well diffusion method, according to the Clinical Laboratory Standard Institute procedure.<sup>45</sup> The bacterial strains were cultured in an incubator at 37 °C for 24 h in a sterile nutrient broth (NB), which was prepared by dissolving 13.0 g of NB powder in 1 L of distilled water. Each culture (10  $\mu\text{L}$ ) was then diluted with 3.0 mL of NB solution to be at 0.5 McFarland standard, which was confirmed based upon its absorbance at 625 nm to be within 0.08–0.13, which is equivalent to an approximate bacterial suspension of  $1.5 \times 10^8 \text{ mL}^{-1}$ .<sup>46</sup> Each bacterial culture (200  $\mu\text{L}$ ) was spread using a sterile glass spreader on a sterilized Muller Hinton (MH) agar plate which was prepared by pouring 25 mL of sterilised agar into a sterile Petri dish.

After drying, six wells were crafted on the agar plate with a 5 mm diameter cork borer. Into four of those wells, 40  $\mu\text{L}$  of SB- $\text{Ag}_2\text{S}$  QDs was added with an approximate concentration of 2  $\text{mg mL}^{-1}$ , while the other two of those wells were respectively filled with similar volume and concentration of streptomycin sulfate and either DMSO or water. The streptomycin was used as

a positive control, whereas DMSO or water was the negative control. Streptomycin was selected as the standard antibacterial agent because it has high solubility in water, it is naturally colourless, it is applicable to inhibit Gram-positive and Gram-negative bacterial strains, and it has a growth inhibition zone that is widely reported in the literature.<sup>47–50</sup> After incubation at 37 °C for 24 h, the diameter of the inhibition zone of bacterial growth on the agar plate was measured. The antibacterial screening test was repeated for at least four replicates, and the inhibition zone was calculated as the average mean value.

The MIC, which represents the lowest concentration of the SB- $\text{Ag}_2\text{S}$  QDs that inhibited the growth of *B. subtilis*, *S. aureus*, *E. coli*, and *P. aeruginosa* bacterial strains after being incubated overnight was evaluated by preparing inoculated bacterial culture in NB to be at 0.5 McFarland standard. The standardized bacterial culture suspension was further diluted with NB solution with a ratio of 1 : 150, and was labelled as standardised inoculum. The SB- $\text{Ag}_2\text{S}$  QDs suspensions in NB solution at different concentrations (20, 10, 5, 2.5, 1.25, 0.625, 0.313, 0.156, 0.0781, and 0.0392  $\text{mg mL}^{-1}$ ) were prepared in 96-well plates by 2-fold dilutions. All the suspensions (50  $\mu\text{L}$ ) were then mixed with the same volume of the standardised inoculum, and the mixtures were then incubated at 37 °C overnight.

The MBC of the SB- $\text{Ag}_2\text{S}$  QDs was investigated against *S. aureus*, bacterial strain by observing the lowest concentration which showed no bacterial growth observable on the MH agar plates. In this test, 200  $\mu\text{L}$  of MH agar was poured into the Petri dish. The agar plates were divided into 4 sections, which could be considered as replications. Once the agar had solidified, a sterile inoculating loop was inserted into the test tubes containing SB- $\text{Ag}_2\text{S}$  QDs and was swabbed onto the surface of the solidified agar. After overnight incubation at 37 °C, the bacterial growth was assessed, and the samples which showed no visible bacterial growth were taken to represent the MBC.<sup>51</sup>

The bacterial growth inhibitions of TGA- $\text{Ag}_2\text{S}$  QDs and the four free Schiff bases used in this study were tested against the same bacterial strains under the same experimental conditions. The diameter of the inhibition zone was recorded, and was compared with those of the SB- $\text{Ag}_2\text{S}$  QDs.

#### 2.6 Fungal growth inhibition

The antifungal activities of the four SB- $\text{Ag}_2\text{S}$  QDs were examined using the agar well diffusion method against colony formation of *Candida albicans* (ATCC 40042), according to the Clinical Laboratory Standard Institute procedure.<sup>45</sup> The fungal cultures were cultivated by inoculating 100  $\mu\text{L}$  of fungal stock culture in 5 mL of NB and these were left incubated in a water bath at 37 °C and agitated at 150 rpm. A cloudy fungal culture was observed after 48 hours, indicating successful fungal growth. The fungal culture was then diluted using NB to ensure that it is equivalent to 0.5 McFarland standard. 200  $\mu\text{L}$  of the standardised culture was poured and homogenized on MHA plates using a sterile spreader and allowed to dry for a few minutes. Six wells were then made in each MHA plate using a 0.5 cm diameter cork borer. Into five of those wells, 40  $\mu\text{L}$  of SB- $\text{Ag}_2\text{S}$  QDs was gently pipetted with an approximate concentration of



2 mg mL<sup>-1</sup>, and 40  $\mu$ L of ultrapure water was pipetted into the sixth well as a negative control. The agar plates were then incubated at 37 °C for 48 hours. Finally, the measurement for the diameter of inhibition zone where there is no fungal growth observed was recorded. The data was collated by taking the mean of the replicates of each sample. The fungal growth inhibitions of TGA-Ag<sub>2</sub>S QDs and the four free Schiff bases were performed under the same experimental condition. The diameter of the inhibition zone was recorded, and was compared with those of the SB-Ag<sub>2</sub>S QDs.

### 2.7 Brine shrimp lethality bioassay

The toxicity of SB-Ag<sub>2</sub>S QDs was established by employing a shrimp lethality bioassay which was performed in 12-well plate. Brine shrimp larvae (*Artemia nauplii* L.) were prepared by hatching the shrimp eggs at 30 °C for 2 days in a shallow rectangular container containing artificial seawater. Ten brine shrimp larvae were collected from the hatching container, and were transferred into each well of triplicate plates, followed by the addition of 0.5 mL aliquots of the QDs samples with different concentrations (100, 10, 1 and 0.1 mg mL<sup>-1</sup>). 0.5 mL of the artificial seawater was used as a negative control. Each well was further adjusted by adding 4.5 mL of artificial seawater, thus the final concentrations of QDs in each well were (10 000, 1000, 100, and 10  $\mu$ g mL<sup>-1</sup>, respectively). The plates were then incubated under illumination at 25–30 °C. After incubation for 24 h, the number of surviving shrimp larvae was recorded. The average percentage lethality was plotted as a function of the logarithm of the QD concentration. The toxicity is defined by the LC<sub>50</sub> which is the lethal concentration killing 50% of the larvae.

## 3. Results and discussion

### 3.1 The formation of Schiff bases-Ag<sub>2</sub>S QDs

The formation of SB-Ag<sub>2</sub>S QDs and TGA-Ag<sub>2</sub>S QDs was confirmed from their characterization data, including visible-NIR absorption and FTIR spectra, EDX and XRD, and TEM imaging. Fig. 2 shows the visible-NIR absorption spectra of SB-Ag<sub>2</sub>S QDs and TGA-Ag<sub>2</sub>S QDs grown at 100 °C for 5 min. The spectra consisted of a baseline rising towards shorter wavelength resulting from elastic Rayleigh scattering and a narrow absorption band at 970 nm assigned to the lowest optical transition of Ag<sub>2</sub>S QDs as reported by Christy *et al.*<sup>52</sup> However, the peak maximum was at slightly shorter wavelength compared to that reported by Sun *et al.* (1010 nm).<sup>53</sup> The absorption bands of SB below 500 nm (Fig. S1†) were not present, because the number of molecules on the surface is too low for their absorption to register above the Rayleigh scattering. The spectra had similar peak maxima, indicating that the particle sizes of the Ag<sub>2</sub>S QDs are also similar.

The FTIR spectra of SB-Ag<sub>2</sub>S QDs are shown in Fig. 3, while the spectra of their respective Schiff bases are shown in Fig. S2.† The FTIR spectra of Ag<sub>2</sub>S QDs showed the characteristic Ag–S and Ag–N vibrations at 420–600 cm<sup>-1</sup>.<sup>54</sup> The broad band at 3450 cm<sup>-1</sup> and shoulder band at 1600 cm<sup>-1</sup> are assigned to the




Fig. 2 The Vis-NIR spectra of (a) 9anSM-Ag<sub>2</sub>S (b) 9anSB-Ag<sub>2</sub>S, (c) AcpysM-Ag<sub>2</sub>S, (d) AcpysB-Ag<sub>2</sub>S, and (e) TGA-Ag<sub>2</sub>S QDs grown at 100 °C for 5 min.

OH stretching and bending vibrational modes of residual water adsorbed onto the Ag<sub>2</sub>S QDs surface.<sup>55</sup> The main vibrational bands at 3080, 2857, 1627, 1552, 956, 735 cm<sup>-1</sup> are assigned to the Schiff bases (N–H, C–H, C=N, C=C aromatics, C=S, and C–S stretching vibrations, respectively).<sup>56,57</sup> It is noteworthy that several of the Schiff base's vibrational bands of the SB-Ag<sub>2</sub>S QDs were shifted to lower frequency or their intensities were suppressed compared to those of the respective free Schiff bases, indicating less electron delocalisation, which is most likely due to the interaction of the thione (–C=S) and imine (–C=N–) moieties to Ag<sub>2</sub>S.

The FTIR spectrum of TGA-Ag<sub>2</sub>S QDs (Fig. 2(e)) showed no S–H vibrational band, which is typically observed at  $\sim$ 2560 cm<sup>-1</sup>, indicating that the TGA coordinates through the thiol group.<sup>30,58</sup> As was the case for SB-Ag<sub>2</sub>S QD, strong bands at 3450 and 1600 cm<sup>-1</sup> are also attributed to the vibrations of




Fig. 3 The FTIR spectra of (a) 9anSM-Ag<sub>2</sub>S, (b) 9anSB-Ag<sub>2</sub>S, (c) AcpysM-Ag<sub>2</sub>S, (d) AcpysB-Ag<sub>2</sub>S, and (e) TGA-Ag<sub>2</sub>S QDs grown at 100 °C for 5 min.



adsorbed water molecules. Importantly, the Ag-S vibration consistently appeared as a broad band at 420–600 cm<sup>-1</sup>.

From the SEM images of SB-Ag<sub>2</sub>S QDs prepared using the colloidal method shown in Fig. S3,† they can be seen to form irregular agglomerates. The particles in the agglomerates were mostly spheroidal with a rough surface morphology. The sizes and surface morphology of agglomerated SB-Ag<sub>2</sub>S QDs were similar to those of TGA-capped Ag<sub>2</sub>S QDs. The SEM-EDX identified and quantified the elements present in the SB-Ag<sub>2</sub>S and TGA-Ag<sub>2</sub>S QDs. As shown in Fig. S3,† the EDX spectrum verified the presence of the elements Ag and S in SB-Ag<sub>2</sub>S QDs with atomic percentage ratio of Ag and S being 54.3 : 27.4, which equates to approximately 2 to 1, confirming the Ag<sub>2</sub>S formation. A similar approximate atomic percentage ratio of Ag and S was also found in TGA-capped Ag<sub>2</sub>S QDs. It is noted that there is a slightly higher atomic percentage of S in the SB-Ag<sub>2</sub>S QDs which may come from the Schiff bases on the QDs surface.

The HRTEM images of **AcpysB**-Ag<sub>2</sub>S QDs and TGA-Ag<sub>2</sub>S QDs along with their particle size distribution are shown in Fig. 4, as typical representative examples. Those of **9anSM**-, **9anSB**-, and **AcpysM**-Ag<sub>2</sub>S QDs are presented in Fig. S4.† The HRTEM images demonstrated that the QDs were nearly spherical and had high crystallinity as seen by their clear lattice fringes.

Based on the TEM images, the particle size distribution of the SB-Ag<sub>2</sub>S QDs was obtained by estimating the diameter of at least 70 particles. The size ranges were 5.6 ± 2.2 nm, 4.8 ± 1.7 nm, 5.0 ± 2.1 nm, and 4.0 ± 1.3 nm, for **AcpysB**-Ag<sub>2</sub>S, **9anSM**-Ag<sub>2</sub>S, **9anSB**-Ag<sub>2</sub>S, and **AcpysM**-Ag<sub>2</sub>S QDs, respectively. The size range of the TGA-Ag<sub>2</sub>S QDs was 6.3 ± 2.4 nm. This confirms that the SB-Ag<sub>2</sub>S QDs are slightly smaller compared to TGA-Ag<sub>2</sub>S QDs in this study and those reported by Wang *et al.* (6.98 nm),<sup>59</sup> and Sun *et al.* (9.0 nm).<sup>53</sup> These results explain the shorter wavelength peak maximum of the NIR absorption band for the SB-Ag<sub>2</sub>S QDs compared to those previously reported for bovine serum albumin (BSA)-Ag<sub>2</sub>S QDs<sup>59</sup> and TGA-Ag<sub>2</sub>S QDs.<sup>53</sup> Since the particle sizes of the SB-Ag<sub>2</sub>S QDs are only slightly larger than the Ag<sub>2</sub>S exciton diameter (in the range of 3.0–4.4 nm),<sup>60</sup> one can expect that these Ag<sub>2</sub>S QDs have a strong quantum confinement effect.

The crystallinity and crystalline phase of the SB-Ag<sub>2</sub>S TGA-Ag<sub>2</sub>S QDs was established using XRD. As shown in Fig. 5, the XRD patterns have diffraction peaks at 26.4°, 29.0°, 31.6°, 33.7°, 34.5°, 34.9°, 36.8°, 37.8°, 40.7°, 43.5°, 45.6°, 46.4°, 48.0°, 48.9°, 53.3° which faithfully match the expected positions of the (−112), (110), (−113), (−121), (−122), (013), (−104), (031), (−202) (−212), (112), (−214), (014), (−224) planes of monoclinic phase  $\alpha$ -Ag<sub>2</sub>S (acanthite; space group no. 14,  $P2_1/c$ ).<sup>61</sup> Based on the XRD patterns, the lattice fringe spacing ( $d$ ) observed in the TEM image (Fig. 4) was estimated using the relation  $d = \lambda / 2 \sin \theta$ ; (where  $\lambda$  is the incident X-ray wavelength and  $\theta$  is the Bragg diffraction angle) and was found to be 0.119 nm, which corresponds to the (−112) facet of the acanthite Ag<sub>2</sub>S.

The large width of the diffraction peaks is a result of the small crystallite sized Ag<sub>2</sub>S nanocrystals.<sup>62</sup> The profile of diffraction band at 34.5°, which had the highest diffraction intensity, was used to estimate the average crystallite size ( $D$ ) of the Ag<sub>2</sub>S QDs using the Scherrer formula;<sup>63</sup>




Fig. 4 The HRTEM images of (A) AcpysB-Ag<sub>2</sub>S QDs and (B) TGA-Ag<sub>2</sub>S QDs, showing their lattice fringes with spacing of 0.119 nm, corresponding to the (−112) plane of acanthite Ag<sub>2</sub>S, and (C) the particle size distribution of AcpysB-Ag<sub>2</sub>S QDs (white bars) and TGA-Ag<sub>2</sub>S QDs (black bars) along with their respective best-fit Gaussian curve.

$$D = \kappa \lambda / \beta (\cos \theta)$$

where  $\kappa$  is the Scherrer constant (0.9) and  $\beta$  is the full width at half-maximum of the Bragg diffraction peak. The average crystallite size of the SB-Ag<sub>2</sub>S and TGA-Ag<sub>2</sub>S QDs was calculated to be 5.1 and 5.8 nm, respectively, which is in good agreement with the sizes determined from TEM images (see Fig. 4), suggesting that the QDs consisted of a single crystalline structure.

The above findings are consistent with the Schiff bases being complexed with Ag<sup>+</sup>, followed by the formation of Ag<sub>2</sub>S salts







Fig. 5 The XRD patterns of (a) 9anSM- $\text{Ag}_2\text{S}$ , (b) 9anSB- $\text{Ag}_2\text{S}$ , (c) AcpysM- $\text{Ag}_2\text{S}$ , (d) AcpysB- $\text{Ag}_2\text{S}$ , and (e) TGA- $\text{Ag}_2\text{S}$  QDs grown at 100 °C for 5 min.

which were aggregated, leading to the formation of SB- $\text{Ag}_2\text{S}$  QDs, as schematically illustrated in Scheme 1. A similar reaction mechanism for  $\text{Ag}_2\text{S}$  QDs has been reported by Jiang *et al.*<sup>10</sup> and Siva *et al.*<sup>64</sup> respectively using 3-mercaptopropionic acid (3-MPA) and L-cysteine as capping agents. This indicates that, in general, the mechanism of the bottom-up synthetic approach of QDs involves similar elementary steps, including the

interaction between the metallic cation with the capping agent, followed by the formation of  $\text{Ag}_2\text{S}$  salts which then crystallize to form the nanocrystals.<sup>65</sup> It is important to recall that the particle sizes of SB- $\text{Ag}_2\text{S}$  QDs were slightly smaller compared to TGA- $\text{Ag}_2\text{S}$  QDs, most probably due to the larger molecular sizes of the Schiff bases compared to TGA, which should inhibit the growth of the QDs preventing them from developing into larger-sized particles.

These findings confirm that SB- $\text{Ag}_2\text{S}$  QDs have been successfully synthesized by a facile one-pot synthesis method, implying that the SBs could chelate  $\text{Ag}^+$  and that the complexes were further neutralized by  $\text{S}^-$  ions and crystallized to form SB- $\text{Ag}_2\text{S}$  QDs. The formation, crystal structure, and physical characteristics of these  $\text{Ag}_2\text{S}$  QDs capped with Schiff base ligands synthesized by the one-pot synthesis method are similar to those of other  $\text{Ag}_2\text{S}$  QDs capped with BSA,<sup>59</sup> TGA,<sup>53</sup> 2-MPA,<sup>30</sup> 3-MPA,<sup>10</sup> D-penicillamine,<sup>31</sup> alkyl,<sup>3</sup> 2-(benzylidene amino)benzothiol,<sup>37</sup> and EDTA<sup>38</sup> prepared *via* one-pot synthesis, one-pot microwave assisted reaction, pyrolysis, chemical condensation, solvothermal, and hydrochemical bath deposition methods. Nevertheless, the particle sizes of SB- $\text{Ag}_2\text{S}$  QDs (4.0–5.6 nm) synthesized by our one-pot synthesis tend to be smaller as compared those  $\text{Ag}_2\text{S}$  QDs prepared with the other methods, such as alkyl- $\text{Ag}_2\text{S}$  QDs (10.2 nm) *via* pyrolysis,<sup>3</sup> 2-(benzylidene amino) benzothiol- $\text{Ag}_2\text{S}$  QDs (42 nm) *via* solvothermal,<sup>37</sup> and EDTA- $\text{Ag}_2\text{S}$  QDs (10–20 nm) *via* hydrochemical bath deposition.<sup>38</sup> This means that the one-pot synthesis is an effective method for producing smaller size-controlled  $\text{Ag}_2\text{S}$  QDs.



Scheme 1 Schematic illustration the mechanism of the formation of 9anSM- $\text{Ag}_2\text{S}$  QDs, as a representative example of the general formation mechanism proposed for SB- $\text{Ag}_2\text{S}$  QDs.



### 3.2 Antibacterial and antifungal activities

The disk diffusion assay results suggested that the SB-Ag<sub>2</sub>S QDs exhibited good antibacterial activities against both Gram-positive (*B. subtilis* and *S. aureus*) and Gram-negative (*E. coli* and *P. aeruginosa*) bacterial strains, with various diameters of inhibition zones, as summarized in Table 1, while the representative images of growth inhibition zones of *B. subtilis* nurtured with Schiff base-Ag<sub>2</sub>S QDs are given in Fig. S6.† This is a qualitative indication that the SB-Ag<sub>2</sub>S QDs have antibacterial activities regardless of the thickness of the peptidoglycan layer or the presence of an outer lipid membrane on the bacterial cells. However, the bacterial growth inhibition zones of the SB-Ag<sub>2</sub>S QDs were approximately two-thirds smaller than those of streptomycin sulfate, suggesting that they have lower antibacterial activities.

Using the same antibacterial screening procedures, the antibacterial activities of the SB-Ag<sub>2</sub>S QDs were also compared with those of the respective free Schiff bases and the TGA-Ag<sub>2</sub>S QDs. In general, except for **AcpysM**, all the Schiff bases in this study and the TGA-Ag<sub>2</sub>S QDs were inactive against the Gram-positive and Gram-negative bacteria. This clearly shows that the antibacterial activities of SB-Ag<sub>2</sub>S QDs is a function of the capping agents. It might further indicate that the Schiff bases on the QDs are more polarised enhancing their interaction with the bacterial cell membrane.

The MIC of the SB-Ag<sub>2</sub>S QDs toward the Gram-positive and Gram-negative bacterial strains were in the range of 5–75 µg mL<sup>−1</sup>, as summarised in Table 2, demonstrating that only low concentrations of the Ag<sub>2</sub>S QDs are required to inhibit the bacterial growth. It is important to highlight that all of the SB-Ag<sub>2</sub>S QDs had an MIC value of 5–10 µg mL<sup>−1</sup> toward *B. subtilis* bacterium. Representative images of the microbroth dilution method to determine the MIC of Schiff base-Ag<sub>2</sub>S QDs to inhibit *B. subtilis* are presented in Fig. S7.† Those of streptomycin and TGA-Ag<sub>2</sub>S QDs are also presented for comparison. These MIC values were even lower or at least comparable to streptomycin (10 µg mL<sup>−1</sup>).<sup>47</sup> In particular, **9anSB**- and **AcpysM**-Ag<sub>2</sub>S QDs have MIC values in the range of 5–11 µg mL<sup>−1</sup> toward *E. coli* bacterium, which is much lower than that of streptomycin (25 µg

mL<sup>−1</sup>),<sup>48</sup> whereas the MIC value of **9anSM**-Ag<sub>2</sub>S QDs toward *P. aeruginosa* bacterium was 6 µg mL<sup>−1</sup>, which is also lower than streptomycin (8 µg mL<sup>−1</sup>).<sup>49</sup> These results show that in certain screening assays the SB-Ag<sub>2</sub>S QDs exhibit even stronger antibacterial activity than streptomycin.

The capability of SB-Ag<sub>2</sub>S QDs to act as antibacterial agents were further confirmed by the susceptibility of Gram-positive, *S. aureus* bacterium. As summarised in Table 2, the MBC of **9anSM**- and **AcpysM**-Ag<sub>2</sub>S QDs were 125 and 250 µg mL<sup>−1</sup>, respectively, while those of **9anSB**- and **AcpysB**-Ag<sub>2</sub>S QDs were 800 µg mL<sup>−1</sup>. In comparison, the MBC of streptomycin sulfate against *S. aureus* has been reported to be in the range between 12 to 18 µg mL<sup>−1</sup>.<sup>50</sup> Based on these MBC values, the Ag<sub>2</sub>S QDs capped with Schiff bases of *S*-methyl-dithiocarbazate derivatives could be considered as bactericidal agents, while those capped with *S*-benzyl-dithiocarbazate derivatives were bacteriostatic agents or bacterial inhibitors.<sup>51</sup> These results highlight that the potential to apply SB-Ag<sub>2</sub>S QDs as new antibacterial agents, causing either bacteriostatic or bactericidal impact where the growth of the bacterial growth is inhibited or the bacteria is even killed.<sup>52</sup>

The SB-Ag<sub>2</sub>S QDs exhibit antifungal activity against *C. albicans*. The mean diameter of inhibition zone of the Schiff bases-Ag<sub>2</sub>S QDs was 11.4–13.6 mm, as shown in Table 1. The inhibition zones of *C. albicans* nurtured with Schiff base-Ag<sub>2</sub>S QDs are shown in Fig. S8.† In contrast, TGA-Ag<sub>2</sub>S QDs and the corresponding free Schiff bases have no detectable antifungal activity. In comparison, the sizes of the inhibition zone of the SB-Ag<sub>2</sub>S QDs against *C. albicans* was slightly larger than those of Ag/In/S QDs (9.5–10 mm).<sup>67</sup> It is likely that the Schiff bases, when attached to the surface of Ag<sub>2</sub>S QDs, can interact with the fungus cell surface damaging the cell wall resulting in either cell growth inhibition or even penetration of the Ag<sub>2</sub>S QDs into the cell due to the permeability of the fungus cell wall. As explained above, this could induce oxidative stress in the cells, which would eventually result in the inhibition of cell growth and even cell death, as described in the literature.<sup>68,69</sup>

The MIC of the SB-Ag<sub>2</sub>S QDs against *C. albicans* were in the range of 40–310 µg mL<sup>−1</sup>, as summarised in Table 2. Images of

**Table 1** The comparison of the inhibition zones of Gram-positive and Gram-negative bacterial strains and fungus by Schiff bases-Ag<sub>2</sub>S QDs and TGA-Ag<sub>2</sub>S QDs along with the standard streptomycin<sup>a</sup>

Sample	Inhibition zone (mm)				
	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>C. albicans</i>
Schiff bases-Ag <sub>2</sub> S QDs	9anSM-Ag <sub>2</sub> S	13.5 ± 0.8	13.8 ± 1.1	13.8 ± 1.2	12.3 ± 1.9
	9anSB-Ag <sub>2</sub> S	12.0 ± 1.0	9.8 ± 0.8	ND	10.5 ± 1.1
	AcpysM-Ag <sub>2</sub> S	12.3 ± 1.3	15.0 ± 2.0	11.0 ± 1.7	14.5 ± 0.7
	AcpysB-Ag <sub>2</sub> S	11.8 ± 0.7	ND	ND	10.8 ± 1.2
Schiff bases	9anSM	ND	ND	ND	ND
	9anSB	ND	ND	ND	ND
	AcpysM	11.5 ± 1.5	9.0 ± 1.9	8.3 ± 1.3	ND
	AcpysB	ND	ND	ND	ND
TGA-Ag <sub>2</sub> S QDs		ND	ND	ND	ND
	Streptomycin	21.3 ± 1.7	21.0 ± 2.9	21.5 ± 1.9	19.0 ± 2.1

<sup>a</sup> ND denotes that no bacterial growth inhibition was detected.



Table 2 The MIC values for Schiff bases-Ag<sub>2</sub>S QDs and streptomycin for comparison

Sample	MIC (μg mL <sup>-1</sup> )					MBC (μg mL <sup>-1</sup> )	
	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>C. albicans</i>	<i>S. aureus</i>	
Schiff bases-Ag <sub>2</sub> S QDs	9anSM-Ag <sub>2</sub> S	5	20	70	6	80	125
	9anSB-Ag <sub>2</sub> S	5	10	5	10	40	800
	AcpysM-Ag <sub>2</sub> S	10	20	11	14	310	250
	AcpysB-Ag <sub>2</sub> S	5	10	50	10	310	800
Streptomycin		10 (ref. 47)	10 (ref. 47)	25 (ref. 48)	8 (ref. 49)	—	12–18 (ref. 50)

the results from the microbroth method to determine the MIC of *C. albicans* nurtured with Schiff base-Ag<sub>2</sub>S QDs are shown in Fig. S8.† The lowest MIC was seen for 9anSB-Ag<sub>2</sub>S QDs, followed by 9anSM-Ag<sub>2</sub>S, AcpysM-Ag<sub>2</sub>S, and AcpysB-Ag<sub>2</sub>S QDs. It is notable that the MIC of the SB-Ag<sub>2</sub>S QDs were much higher than that of other Ag nanoparticles (1–7 μg mL<sup>-1</sup>),<sup>70</sup> but much lower compared with ibuprofen (2048 μg mL<sup>-1</sup>).<sup>71</sup> This result confirms that the SB-Ag<sub>2</sub>S QDs also act as antifungal agent and inhibit fungal growth.

Antibacterial and antifungal mechanism of functionalized QDs and low-dimensional materials have been summarized by Rajendiran *et al.*<sup>68</sup> and Shaw *et al.*<sup>72</sup> It has been pointed out that the most commonly proposed antimicrobial mechanism of QDs involves chemical interferences and oxidative stress, leading to membrane damage, protein dysfunction, nucleic acid fragmentation, and transcriptional arrest.<sup>73</sup> In particular, the QDs interact with the phospholipid layer of bacterial membranes, and metallic ions on their surface disrupt the cell respiration and cellular pathways.<sup>74</sup> The oxidative stress due to intracellular reactive oxygen species generated upon interaction between the QDs with the bacterial cells disrupts phospholipids, nucleic acids, proteins, resulting in cell lysis.<sup>75</sup> Surface chemical functionalisation is considered to enhance the production of reactive oxygen species, destroying the cell wall, and disrupting nucleic acids.<sup>76</sup> In this sense, one could consider the QDs functionalized with highly π-conjugated compounds would accelerate charge separation and the production of reactive oxygen species.<sup>72</sup> Taking this into account, one possible mechanism for the antimicrobial action is that there is an interaction between the Schiff bases on the Ag<sub>2</sub>S QDs surface and the bacterial cell wall or cell membrane which creates oxidative stress and damage the cell wall, leading to cell rupture.<sup>77,78</sup> This proposed interaction of the QD-bound Schiff bases and the bacterial cells is supported by the fact that there should be an electrostatic attraction between the positively charged QDs and the negatively charged phospholipid bilayer of the bacterial cell.<sup>77,78</sup> It has also been proposed that metal oxide QDs can transfer an electron into the bacterial cell or produce reactive oxygen species (ROS), increasing cytotoxicity by producing reactive oxygen species within the cell, which would inhibit metabolic processes and kill the cell,<sup>77–79</sup> and this would also apply to SB-Ag<sub>2</sub>S QDs. In this sense, a synergistic cooperative effect between the Schiff bases and the Ag<sub>2</sub>S core is proposed for the antibacterial activities of SB-Ag<sub>2</sub>S QDs. The Schiff bases are highly conjugated across the entire molecule, whereas TGA is

not. Therefore, the conjugated electron clouds on the Schiff bases should facilitate electron transfer to the pathogen cell walls, whereas the unconjugated TGA would insulate the Ag<sub>2</sub>S core preventing electron transfer.

The electron transfer mechanism is proposed based on the possibility of dark (thermalized) electron transfer from Ag<sub>2</sub>S to the Schiff's base and to the cell wall. The principle reason for our argument is that, Fermi levels in Ag<sub>2</sub>S is 10 eV, with a bandgap of ~1 eV.<sup>8</sup> The Ag<sub>2</sub>S band gap can be exceeded, and the conduction band can be populated at room temperature.<sup>42</sup> Furthermore, it is well understood that π-conjugated molecules such as Schiff bases have a higher HOMO energy levels and a lower LUMO energy levels, which would facilitate more efficient electron hopping (transfer) from the Ag<sub>2</sub>S to the Schiff bases LUMO. The energy of the LUMO level should generally follow the trend of the degree of conjugation. Consequently, if our proposed mechanism is reasonable, the antibacterial and antifungal activity should generally follow the same trend, which indeed it is demonstrated in this study.

We may also recall that Ag<sub>2</sub>S conduction band is similar in energy to a typical organic dye's excited state or even higher.<sup>27,28</sup> Therefore, a thermally excited electron hopping from the Ag<sub>2</sub>S conduction band through the organic dye's excited state (LUMO) is not only feasible in terms of the energetics of the system but it is very likely to happen. Nevertheless, we do not rule out electron transfer from the Fermi level, if the LUMO of the dye is lower in energy than the Fermi level. Therefore, attaching Schiff bases as capping agents is not just the conjugation providing a "conducting" bridge between the Ag<sub>2</sub>S and the cell wall, it is the relative LUMO energies of the Schiff bases with respect to the Ag<sub>2</sub>S conduction band and Fermi level that would be important. Once inside the Schiff base LUMO, the electron can further interact with the typical electron acceptors in the cell wall, as well as with water in the medium to produce ROS, which are well established as precursors that produce cell death in dark (non-light-initiated) reactions.<sup>77</sup>

### 3.3 Toxicity test

The results of toxicity of SB-Ag<sub>2</sub>S QDs against *A. nauplii* shrimp larvae are presented in Table S1.† Based on a total larvae number of 360 from triplicates, at the concentrations of SB-Ag<sub>2</sub>S QDs of 10 000, 1000, 100, and 10 μg mL<sup>-1</sup>, the average larval deaths were found to be in the range of 0 to 40%. At the lowest QD concentration of 10 μg mL<sup>-1</sup> the mortality of larvae in the presence of the Ag<sub>2</sub>S QDs was 0%, except for AcpysB-Ag<sub>2</sub>S QDs



which induced larval mortality of 3.3%. The mortality of larvae increased with QDs concentration, and in the highest QDs concentration of  $10\,000\,\mu\text{g mL}^{-1}$ , the mortality was in the range of 5.1–39.5%, revealing that among the SB- $\text{Ag}_2\text{S}$  QDs, **AcpySB- $\text{Ag}_2\text{S}$**  QDs was the most toxic, followed by **9anSB-**, **AcpySM-**, and then the **9anSM- $\text{Ag}_2\text{S}$**  QDs. In comparison, TGA- $\text{Ag}_2\text{S}$  QDs even in its highest concentration showed mortality of larvae of less than 3%. It is notable that  $\text{LC}_{50}$  values of SB- $\text{Ag}_2\text{S}$  QDs were more than  $1000\,\mu\text{g mL}^{-1}$ , suggesting that the SB- $\text{Ag}_2\text{S}$  QDs were not toxic to *A. nauplii* shrimp.<sup>30</sup>

## 4. Conclusions

$\text{Ag}_2\text{S}$  QDs have been made in a one-pot synthesis. In this study, for the first time, four different Schiff bases of *S*-methyl- or *S*-benzyl-dithiocarbazate derivatives have been used as stabilizing agents. The SB- $\text{Ag}_2\text{S}$  QDs were nearly spherical with average sizes being in the range of 4.0 nm to 5.6 nm, which is smaller compared to conventional thioglycolic acid (TGA)-capped  $\text{Ag}_2\text{S}$  QDs. It was confirmed that the SB- $\text{Ag}_2\text{S}$  QDs had good antibacterial activities against Gram-positive and Gram-negative bacterial strains as well as antifungal activities against *C. albicans*. This was in contrast to the biologically inactive or low activity TGA capped  $\text{Ag}_2\text{S}$  QDs and respective free Schiff bases. It is therefore concluded that the bioactivities of the SB- $\text{Ag}_2\text{S}$  QDs is a function of the cooperative interaction between Schiff bases as capping agents, which enhances an electrostatic attraction between the positively charged QDs with the negatively charged phospholipid bilayer of the bacterial cell wall and glucans and glycoproteins of fungus cell wall, destroying the membrane cell walls. The MIC results confirmed that it only required low concentrations of the SB- $\text{Ag}_2\text{S}$  QDs to inhibit the growth *B. subtilis*, *E. coli*, and *P. aeruginosa* bacterial strains as well as *C. albicans*, which were to some extent comparable or lower than those of streptomycin and ibuprofen. This confirms their strong capacity to inhibit bacterial and fungal growth. The  $\text{Ag}_2\text{S}$  QDs capped with Schiff bases of *S*-methyl-dithiocarbazate derivatives could be considered as bactericidal agents, while those capped with *S*-benzyl-dithiocarbazate derivatives were bacteriostatic agents or bacterial inhibitors. Overall, this study reports novel functionalized  $\text{Ag}_2\text{S}$  QDs using Schiff bases as capping agents for antimicrobial applications. The conjugated electron clouds on the Schiff bases should facilitate electron transfer to the pathogen cell walls, whereas the unconjugated TGA would insulate the  $\text{Ag}_2\text{S}$  core preventing electron transfer. Results of lethality assay revealed that SB- $\text{Ag}_2\text{S}$  QDs were not toxic to brine shrimp (*Artemia salina*). The investigation on antimicrobial and anticancer activities are of further interest to explore as other possible biological applications of these novel SB- $\text{Ag}_2\text{S}$  QDs.

## Author statement

N.-N. M. Shahri performed the experiments. H. Taha analysed the antibacterial activity. M. H. S. A. Hamid facilitated the syntheses of Schiff bases. E. Kusrini analysed XRD data, J.-W. Lim analysed HRTEM data, J. Hobley analysed data and

reviewed the manuscript, and A. Usman conceived the project and wrote the manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors would like to acknowledge Elena Babai@Endru for her assistance in the early stages of MIC analysis. EK is grateful to Universitas Indonesia for PUTI Q1 Research Grant No: NKB-4036/UN2.RST/HKP.05.00/2020. JH is grateful to NCKU90 for providing his Distinguished Visiting Scientist position.

## References

- 1 C. T. Matea, T. Mocan, F. Tabaran, T. Pop, O. Mosteanu, C. Puia, C. Iancu and L. Mocan, *Int. J. Nanomed.*, 2017, **12**, 5421–5431.
- 2 K. Xiong, J. Li, L. Tan, Z. Cui, Z. Li, S. Wu, Y. Liang, S. Zhu and X. Liu, *Colloid Interface Sci. Commun.*, 2019, **33**, 100201.
- 3 Y. Du, B. Xu, M. Cai, F. Li, Y. Zhang and Q. Wang, *J. Am. Chem. Soc.*, 2010, **132**, 1470–1471.
- 4 I. G. Theodorou, Z. A. R. Jawad, H. Qin, E. O. Aboagye, A. E. Porter, M. P. Ryan and F. Xie, *Nanoscale*, 2016, **8**, 12869–12873.
- 5 K. Akamatsu, S. Takei, M. Mizuhata, A. Kajinami, S. Deki, S. Takeoka, M. Fujii, S. Hayashi and K. Yamamoto, *Thin Solid Films*, 2000, **359**, 55–60.
- 6 J. Xue, J. Liu, S. Mao, Y. Wang, W. Shen, W. Wang, L. Huang, H. Li and J. Tang, *Mater. Res. Bull.*, 2018, **106**, 113–123.
- 7 D. Aydemir, M. Hashemkhani, H. Y. Acar and N. N. Ulusu, *Mol. Biol. Rep.*, 2020, **47**, 4117–4129.
- 8 S. Kashida, N. Watanabe, T. Hasegawa, H. Iida, M. Mori and S. Savrasov, *Solid State Ionics*, 2003, **158**, 167–175.
- 9 K.-Y. Yong, I. Roy, H. Ding, E. J. Bergey and P. N. Prasad, *Small*, 2009, **5**, 1997–2004.
- 10 P. Jiang, C.-N. Zhu, Z.-L. Zhang, Z.-Q. Tian and D.-W. Pang, *Biomaterials*, 2012, **33**, 5130–5135.
- 11 G. Hong, J. T. Robinson, Y. Zhang, S. Diao, A. L. Antaris, Q. Wang and H. Dai, *Angew. Chem., Int. Ed. Engl.*, 2012, **51**, 9818–9821.
- 12 F. D. Duman, I. Hocaoglu, D. G. Ozturk, D. Gazuacik, A. Kiraz and H. Y. Acar, *Nanoscale*, 2015, **7**, 11352–11362.
- 13 O. Bruns, T. Bischof, D. Harris, D. Franke, Y. Shi, L. Riedemann, A. Bartelt, F. B. Jaworski, J. A. Carr, C. J. Rowlands, M. W. B. Wilson, O. Chen, H. Wei, G. Hwang, D. M. Montana, I. Coropceanu, O. B. Achorn, J. Kloepper, J. Heeren, P. T. C. So, D. Fukumura, K. F. Jensen, R. K. Jain and M. G. Bawendi, *Nat. Biomed. Eng.*, 2017, **1**, 0056.
- 14 B. Purushothaman and J. M. Song, *Biomater. Sci.*, 2021, **9**, 51–69.
- 15 D. Bera, L. Qian, T. K. Tseng and P. H. Holloway, *Materials*, 2010, **3**, 2260–2345.



16 E. Navarrete, V. Rojas, M. Romero, J. Román, G. Cáceres, R. Henríquez, P. Grez, R. Schrebler, F. Herrera and E. Muñoz, *J. Solid State Electrochem.*, 2021, **25**, 133–140.

17 A. Mansur, H. Mansur and J. González, *Sensors*, 2011, **11**, 9951–9972.

18 Z. Y. Chen, H. N. Abdelhamid and H. F. Wu, *Rapid Commun. Mass Spectrom.*, 2016, **30**, 1403–1412.

19 B. R. Singh, S. Dwivedi, A. A. Al-Khedhairy and J. Musarrat, *Colloids Surf., B*, 2011, **85**, 207–213.

20 K. Shivaji, S. Mani, P. Ponmurugan, C. S. De Castro, M. L. Davies, M. G. Balasubramanian and S. Pitchaimuthu, *ACS Appl. Nano Mater.*, 2018, **1**, 1683–1693.

21 S. A. Matar, W. H. Talib, M. S. Mustafa, M. S. Mubarak and M. A. AlDamen, *Arabian J. Chem.*, 2015, **8**, 850–857.

22 E. Yousif, A. Majeed, K. Al-Sammarae, N. Salih, J. Salimon and B. Abdullah, *Arabian J. Chem.*, 2017, **10**, 1639–1644.

23 C. M. da Silva, D. L. da Silva, L. V. Modolo, R. B. Alves, M. A. de Resende, C. V. B. Martins and Â. Fátima, *J. Adv. Res.*, 2011, **2**, 1–8.

24 K. M. Khan, N. Ambreen, A. Karim, S. Saied, A. Amyn, A. Ahmed and S. Perveen, *J. Pharmacol. Res.*, 2012, **5**, 651–656.

25 S. Murtaza, M. S. Akhtar, F. Kanwal, A. Abbas, S. Ashiq and S. Shamim, *J. Saudi Chem. Soc.*, 2017, **21**, S359–S372.

26 G. Matela, *Adv. Anticancer Agents Med. Chem.*, 2020, **20**, 1908–1917.

27 C. Chen, Z. Li, H. Lin, G. Wang, J. Liao, M. Li, S. Lv and W. Li, *Dalton Trans.*, 2016, **45**, 3750–3758.

28 L. Cheng, H. Ding, C. Chen and N. Wang, *J. Mater. Sci.: Mater. Electron.*, 2016, **27**, 3234–3239.

29 N. S. Kozhevnikova, A. S. Vorokh, E. V. Shalaeva, I. V. Baklanova, A. P. Tyutyunnik, V. G. Zubkov, A. A. Yushkov and V. Yu Kolosov, *J. Alloys Compd.*, 2017, **712**, 418–424.

30 I. Hocaoglu, M. N. Çizmeciyán, R. Erdem, C. Ozen, A. Kurt, A. Sennaroglu and H. Y. Acar, *J. Mater. Chem.*, 2012, **22**, 14674–14681.

31 Q. Ren, Y. Ma, S. Zhang, L. Ga and J. Ai, *ACS Omega*, 2021, **6**, 6361–6367.

32 Q. Liu, Y. Pu, Z. Zhao, J. Wang and D. Wang, *Trans. Tianjin Univ.*, 2020, **26**, 273–282.

33 Y. Xu, J. Suthar, R. Egbu, A. J. Weston, A. M. Fogg and G. R. Williams, *J. Solid State Chem.*, 2018, **258**, 320–327.

34 J. Xue, H. Li, J. Liu, Y. Wang, Y. Liu, D. Sun, W. Wang, L. Huang and J. Tang, *Mater. Lett.*, 2019, **242**, 143–146.

35 L. Dong, Y. Chu, Y. Liu and L. Li, *J. Colloid Interface Sci.*, 2008, **317**, 485–492.

36 W. Yang, T. Xie, T. Jiang and D. Wang, *Colloids Surf., A*, 2013, **433**, 55–58.

37 M. Shakouri-Arani and M. Salavati-Niasari, *Spectrochim. Acta, Part A*, 2014, **133**, 463–471.

38 S. I. Sadovnikov, Y. V. Kuznetsova and A. A. Rempel, *Nano-Struct. Nano-Objects*, 2016, **7**, 81–91.

39 D. O. Vardar, S. Aydin, I. Hocaoglu, F. H. Y. Acar and N. Basaran, *Chem.-Biol. Interact.*, 2018, **291**, 212–219.

40 O. V. Ovchinnikov, I. G. Grevtseva, M. S. Smirnov, T. S. Kondratenko, A. S. Perepelitsa, S. V. Aslanov, V. U. Khokhlov, E. P. Tatyana and A. S. Matsukovich, *Opt. Quantum Electron.*, 2020, **52**, 198.

41 S. I. Sadovnikov, A. I. Gusev, E. Y. Gerasimov and A. A. Rempel, *Inorg. Mater.*, 2016, **52**, 441–446.

42 A. D. Iacovo, C. Venettacci, L. Colace, L. Scopa and S. Foglia, *Sci. Rep.*, 2016, **6**, 37913.

43 M. H. S. A. Hamid, M. A. Ali, A. H. Mirza, P. V. Bernhardt, B. Moubaraki and K. S. Murray, *Inorg. Chim. Acta*, 2009, **362**, 3648–3656.

44 X. Zhang, M. Liu, H. Liu and S. Zhang, *Biosens. Bioelectron.*, 2014, **56**, 307–312.

45 CLSI, *Performance standards for antimicrobial disk susceptibility tests; approved standard, M02-A13*, Clinical and Laboratory Standards Institute, Wayne, PA, USA, 12th edn, 2018.

46 P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover and R. H. Yolken, *Manual of Clinical Microbiology*, ASM, Washington, DC, 7th edn, 1999.

47 A. M. Clark, A. S. El-Ferally and W. -S. Li, *J. Pharm. Sci.*, 1981, **70**, 951–952.

48 T. S. Rejiniemon, M. V. Arasu, V. Duraipandian, K. Ponmurugan, N. A. Al-Dhabi, S. Arokiyaraj, P. Agastian and K. C. Choi, *Ann. Clin. Microbiol. Antimicrob.*, 2014, **13**, 1–9.

49 F. Khan, J. W. Lee, D. T. N. Pham, J. H. Lee, H. W. Kim, Y. K. Kim and Y. M. Kim, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 799–816.

50 M. Imran, M. Imran and S. Khan, *J. Appl. Pharm. Sci.*, 2017, **7**, 168–174.

51 P. Parvekar, J. Palaskar, S. Metgud, R. Maria and S. Dutta, *Biomater. Invest. Dent.*, 2020, **7**, 105–109.

52 R. S. Christy, J. T. T. Kumaran and C. Bansal, *Adv. Sci. Focus*, 2014, **2**, 115–120.

53 J. Sun, W. Yu, A. Usman, T. T. Isimjan, S. DGobbo, E. Alarousu, K. Takanabe and O. F. Mohammed, *J. Phys. Chem. Lett.*, 2014, **5**, 659–665.

54 G. A. Bowmaker, Effendy, P. C. Junk, B. W. Skelton and A. H. White, *Z. Naturforsch., B: Chem. Sci.*, 2004, **59**, 1277–1292.

55 Y.-Y. Kim and D. Walsh, *Nanoscale*, 2010, **2**, 240–247.

56 M. Das and S. E. Livingstone, *Inorg. Chim. Acta*, 1976, **19**, 5–10.

57 M. A. Ali and M. T. H. Tarafdar, *J. Inorg. Nucl. Chem.*, 1977, **39**, 1785–1791.

58 T. S. Kondratenko, A. I. Zvyagin, M. S. Smirnov, I. G. Grevtseva, A. S. Perepelitsa and O. V. Ovchinnikov, *J. Lumin.*, 2019, **208**, 193–200.

59 G. Wang, J. Liu, L. Zhu, Y. Guo and L. Yang, *RSC Adv.*, 2019, **9**, 29936.

60 Y. Zhang, Y. Liu, C. Li, X. Chen and W. Wang, *J. Phys. Chem. C*, 2014, **118**, 4918–4923.

61 S. I. Sadovnikov and A. I. Gusev, *J. Mater. Chem. A*, 2017, **5**, 17676.

62 V. Nandwana, K. E. Elkins, N. Poudyal, G. S. Chaubey, K. Yano and J. P. Liu, *J. Phys. Chem. C*, 2007, **111**, 4185–4189.

63 D. W. Lucey, D. J. MacRae, M. Furis, Y. Sahoo, A. N. Cartwright and P. N. Prasad, *Chem. Mater.*, 2005, **17**, 3754–3762.



64 C. Siva, C. N. Iswarya, P. Baraneedharan and M. Sivakumar, *Mater. Lett.*, 2014, **134**, 56–59.

65 N. Gaponik, D. V. Talapin, A. L. Rogach, H. Kathrin, E. V. Shevchenko, K. Andreas, A. Eychmüller and H. Weller, *J. Phys. Chem. B*, 2002, **106**, 7177–7185.

66 K. Y. Rhee and D. F. Gardiner, *Clin. Infect. Dis.*, 2004, **39**, 755–756.

67 I. A. Mir, V. S. Radhakrishnan, K. Rawat, T. Prasad and H. B. Bohidar, *Sci. Rep.*, 2018, **8**, 9322–9333.

68 K. Rajendiran, Z. Zhao, D. S. Pei and A. Fu, *Polymers*, 2019, **11**, 1–13.

69 H. S. Devi, M. A. Boda, M. A. Shah, S. Parveen and A. H. Wani, *Green Process. Synth.*, 2019, **8**, 38–45.

70 K.-J. Kim, W. S. Sung, S.-K. Moon, J.-S. Chooi, J. G. Kim and D. G. Lee, *J. Microbiol. Biotechnol.*, 2008, **8**, 1482–1484.

71 P. M. S. Sousa, *Rev. Colomb. Cienc. Quim.-Farm.*, 2020, **49**, 374–386.

72 Z. L. Shaw, S. Kuriakose, S. Cheeseman, M. D. Dickey, J. Genzer, A. J. Christofferson, R. J. Crawford, C. F. McConville, J. Chapman, V. K. Truong, A. Elbourne and S. Walia, *Nat. Commun.*, 2021, **12**, 3897.

73 R. Javed, M. Zia, S. Naz, S. O. Aisida, N. Ain and Q. Ao, *J. Nanobiotechnol.*, 2020, **18**, 172.

74 D. A. Geraldo, N. Arancibia-Miranda, N. A. Villagra, G. C. Mora and R. Arratia-Perez, *J. Nanopart. Res.*, 2012, **14**, 1286–1294.

75 K. Zheng, M. I. Setyawati, D. T. Leong and J. Xie, *ACS Nano*, 2017, **11**, 6904–6910.

76 Z. Li, L. Wu, H. Wang, W. Zhou, H. Liu, H. Cui, P. Li, P. K. Chu and X.-F. Yu, *ACS Appl. Nano Mater.*, 2019, **2**, 1202–1209.

77 P. Patra, S. Roy, S. Sarkar, S. Mitra, S. Pradhan, N. Debnath and A. N. Goswami, *Appl. Nanosci.*, 2015, **5**, 857–866.

78 A. Dasari and V. Guttena, *J. Photochem. Photobiol. B*, 2016, **157**, 57–69.

79 S. Ostrovsky, G. Kazimirsky, A. Gedanken and C. Brodie, *Nano Res.*, 2009, **2**, 882–890.

80 E. Kamyab, S. Rohde, M. Y. Kellermann and P. J. Schupp, *Molecules*, 2020, **25**, 4808.

